The evolution of Staphylococcus aureus during the modern antibiotic era has been
delineated by distinct strain emergence events, many of which include acquisition of …

Clinical management of Staphylococcus aureus infections presents a challenge due to the
high incidence, considerable virulence, and emergence of drug resistance mechanisms …

Staphylococcus epidermidis is a conspicuous member of the human microbiome, widely
present on healthy skin. Here we show that S. epidermidis has also evolved to become a …

SUMMARY “Heteroresistance” describes a phenomenon where subpopulations of
seemingly isogenic bacteria exhibit a range of susceptibilities to a particular antibiotic …

Glycopeptide antibiotics have been a key weapon in the fight against bacterial infections for
over half a century, with the progenitors, vancomycin (1) and teicoplanin (2), still used …

Staphylococcus (S.) aureus silently stays as our natural flora, and yet sometimes threatens
our life as a tenacious pathogen. In addition to its ability to outwit our immune system, its …

Since the discovery of the first strain in 1961 in England, MRSA, the most notorious
multidrug-resistant hospital pathogen, has spread all over the world. MRSA repeatedly …

Vancomycin has been used as the last resort in the clinical treatment of serious
Staphylococcus aureus infections. Vancomycin-intermediate S. aureus (VISA) was …

The emergence of drug-resistant pathogens poses a major threat to public health. Although
influenced by multiple factors, high-level resistance is often associated with mutations in …

Most clinical MRSA (methicillin-resistant S. aureus) isolates exhibit low-level β-lactam
resistance (oxacillin MIC 2–4 μg/ml) due to the acquisition of a novel penicillin binding …